Ianalumab re-treatment for ITP or wAIHA
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a re-treatment with ianalumab for people with ITP or warm-antibody autoimmune hemolytic anemia who previously benefited from the drug in an earlier Novartis study but then had their condition return after at least 2 years. It aims to see if a second course can help again.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been in a previous Novartis study for ITP or wAIHA where you received ianalumab or a placebo.
- You had a good response to treatment in that earlier study, but your condition came back at least 2 years after the last dose.
- You are not using any other treatments for ITP or wAIHA besides the study drug or allowed rescue therapies.
- You do not have other autoimmune blood disorders (like Evans syndrome) or current life-threatening bleeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug, tafasitamab, for people with immune thrombocytopenia (ITP) or warm autoimmune hemolytic anemia (wAIHA) that has not been controlled well by other treatments. The goal is to see if it is safe and can help manage these blood cell disorders.
This study tests a new combination of two medicines (ianalumab and eltrombopag) for children with a blood condition called ITP (low platelets causing bruising and bleeding) who haven't improved with steroids. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
This trial tests a new drug called ianalumab combined with a standard platelet-boosting medicine (TPO-RA) for adults with immune thrombocytopenia (ITP) or Evans syndrome. The goal is to see if the combination is well-tolerated and helps raise platelet counts.
This study tests a new drug called enatumab that may help people with a type of autoimmune anemia where the body attacks its own red blood cells. If you have not responded to previous treatments or your condition has returned, this trial might offer a new option to improve your hemoglobin levels.
This trial tests a new medicine for people with autoimmune hemolytic anemia (AIHA) that has not improved with standard treatments. The goal is to see if the drug can help control the disease and improve red blood cell counts.
This trial tests a new treatment using modified immune cells (CAR T-cells) to target and destroy the faulty cells that attack your blood cells in ITP or wAIHA. It aims to reset your immune system to stop the disease and improve blood counts.
Hear when a new Primary Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.